Citations

Clear

1526 citation(s) found for "Sun, C".

Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial.
Javle, Milind , Fonkoua, Lionel Aurelien Kankeu , Pelster, Meredith S. , Liao, Chih‐Yi , Richards, Donald , Deming, Dustin A. , Younes, Mohamad, Mantry, Parvez , Cohn, Allen Lee, Kingsley, Ed, Peng, Peng , Sun, Caixia, Wang, Hui , Hennessy, Katie , Shan, Yujun, Wu, Frank , Mahipal, Amit , Fountzilas, Christos , Li, Daneng , Fan, Jean , Shan, Yujun

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: 434-434

10.1200/jco.2024.42.3_suppl.434 Get It

434 Background: Tinengotinib is a spectrum-selective multi-kinase inhibitor with unique binding properties to FGFR, potently inhibited FGFR2 fusion/rearrangement and acquired resistant mutations in pre-clinical models and in phase I trials that included cholangiocarcinoma (CCA) patients (pts). Here we present the efficacy and safety of tinengotinib in a phase II clinical trial. Methods: Eligible pts with advanced/metastatic CCA who had received ≥ 1 prior systemic chemotherapy therapy and ECOG PS 0 or 1 were treated with tinengotinib 10 mg QD. Four cohorts included: Cohort A1: FGFR2 fusion(s) with primary progression on previous FGFR inhibitor ( FGFRi), A2: FGFR2 fusion(s) with progression after prior response to FGFRi (acquired resistance); B: non-fusion FGFR alteration(s): C: FGFR wild-type ( FGFRwt). Primary endpoint was objective response rate (ORR) per RECIST v1.1. CTCAE V5.0 was used for safety assessments. Results: As of 7Aug2023, 48 pts with CCA were enrolled, 13 in Cohort A1, 10 in A2, 12 in B, 13 in C. Median age 61.5 [range 25-81] years old, 41.7% male, 58.3% had ≥ 3 lines of prior therapy. ECOG PS 0 in 47.9% pts. Among 35 pts with FGFR alterations, 80.0% had ≥ 1 prior FGFRi therapy, and 97.1% had prior chemotherapy. Forty (40) pts were efficacy evaluable. In A1, 1 out of 11 pts (9.1%) achieved PR with tumor reduction of 31.8%. In A2, 3 out of 8 pts (37.5%) achieved PR with tumor reduction of 40.7%, 47.0% and 54.6%. In B, 3 out of 9 pts (33.3%) achieved PR with tumor reduction of 36.5%, 48.6%, and 60.6%. No PR was observed in C. Overall DCR was 94.7% (18/19) in FGFR2 fusion/rearrangement pts (A1+A2), 88.9% (8/9) in other FGFR alterations pts (B), and 75% (9/12) in FGFRwt pts (C). Median progression-free survival (mPFS) was 5.26 months (95%CI, 2.86-9.10) in A1+A2, 5.98 months (95%CI, 1.87-NA) in B and 3.84 months (95% CI, 1.84-4.80) in C. Among 48 treated pts, treatment-related AEs (TRAEs) occurred in 45 (93.8%) pts, 14 (29.2%) in G1-2, 29 (60.4%) in G3 and 2 (4.2%) in G4. The most common G3 TRAEs were hypertension in 12 (25%), palmar-plantar erythrodysesthesia syndrome in 3 (6.3%), diarrhea in 3 (6.3%) and stomatitis in 3 (6.3%). One subject had G4 increased TSH and G4 increased lipase, and another subject had G4 posterior reversible encephalopathy syndrome. No G5 TRAE was observed. Conclusions: Tinengotinib has promising clinical benefit for FGFR2 fusion CCA after prior FGFRi and for non-fusion FGFR alterations. Tinengotinib-related toxicities were manageable. An ongoing randomized, controlled phase III study will evaluate the clinical efficacy, safety, and pharmacodynamic effect of Tinengotinib vs Physicians’ choice in subjects with FGFR2-altered refractory/relapsed CCA after prior chemotherapy and FGFRi therapy. Clinical trial information: NCT04919642 .
Epidemiologic Factors in Relation to Colorectal Cancer Risk and Survival by Genotoxic Colibactin Mutational Signature
Thomas, Claire E. , Georgeson, Peter , Qu, Conghui , Steinfelder, Robert S. , Buchanan, Daniel D. , Song, Mingyang , Harrison, Tabitha A. , Um, Caroline Y. , Hullar, Meredith A.J. , Guelpen, Bethany Van , Huyghe, Jeroen R. , Aglago, Elom K. , Berndt, Sonja I. , Drew, David A. , Figueiredo, Jane C. , French, Amy J. , Giannakis, Marios , Goode, Ellen L. , Gruber, Stephen B. , Gsur, Andrea , Hoffmeister, Michael , Huang, Wen‐Yi , Newton, Christina C. , Obón‐Santacana, Mireia , Zaidi, Syed Hassan Ejaz , Peters, Ulrike , Phipps, Amanda I. , Hullar, Meredith A , Jenkins, Mark A , Van Guelpen, Bethany , Lynch, Brigid M , Melaku, Yohannes Adama , Huyghe, Jeroen R , Aglago, Elom K , Berndt, Sonja I , Boardman, Lisa , Campbell, Peter T , Cao, Yin , Chan, Andrew T , Drew, David A , Figueiredo, Jane C , Giannakis, Marios , Goode, Ellen L , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Hoffmeister, Michael , Hsu, Li , Huang, Wen-Yi , Moreno, Victor , Murphy, Neil , Newcomb, Polly A. , Newton, Christina C , Nowak, Jonathan A , Obón-Santacana, Mireia , Ogino, Shuji , Sun, Wei , Toland, Amanda Ewart , Trinh, Quang M , Ugai, Tomotaka , Zaidi, Syed H , Peters, Ulrike , Phipps, Amanda I , Buchanan, Daniel D , Harrison, Tabitha A , Um, Caroline Y , Song, Mingyang , Georgeson, Peter , Qu, Conghui , Steinfelder, Robert S , Thomas, Claire E , Jenkins, Mark A. , Boardman, Lisa A. , Campbell, Peter T. , Cao, Yin , Chan, Andrew T. , Gunter, Marc J. , Moreno, Vı́ctor , Murphy, Neil , Nowak, Jonathan A. , Sun, Wei , Trinh, Quang M.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 22, 2024 | Volume: 33 | Issue: 4 | Pages: 534-546

10.1158/1055-9965.epi-23-0600 | PMID 38252034 Get It

Abstract Background: The genotoxin colibactin causes a tumor single-base substitution (SBS) mutational signature, SBS88. It is unknown whether epidemiologic factors’ association with colorectal cancer risk and survival differs by SBS88. Methods: Within the Genetic Epidemiology of Colorectal Cancer Consortium and Colon Cancer Family Registry, we measured SBS88 in 4,308 microsatellite stable/microsatellite instability low tumors. Associations of epidemiologic factors with colorectal cancer risk by SBS88 were assessed using multinomial regression (N = 4,308 cases, 14,192 controls; cohort-only cases N = 1,911), and with colorectal cancer–specific survival using Cox proportional hazards regression (N = 3,465 cases). Results: 392 (9%) tumors were SBS88 positive. Among all cases, the highest quartile of fruit intake was associated with lower risk of SBS88-positive colorectal cancer than SBS88-negative colorectal cancer [odds ratio (OR) = 0.53, 95% confidence interval (CI) 0.37-0.76; OR = 0.75, 95% CI 0.66–0.85, respectively, Pheterogeneity = 0.047]. Among cohort studies, associations of body mass index (BMI), alcohol, and fruit intake with colorectal cancer risk differed by SBS88. BMI ≥30 kg/m2 was associated with worse colorectal cancer–specific survival among those SBS88-positive [hazard ratio (HR) = 3.40, 95% CI 1.47–7.84], but not among those SBS88-negative (HR = 0.97, 95% CI 0.78–1.21, Pheterogeneity = 0.066). Conclusions: Most epidemiologic factors did not differ by SBS88 for colorectal cancer risk or survival. Higher BMI may be associated with worse colorectal cancer–specific survival among those SBS88-positive; however, validation is needed in samples with whole-genome or whole-exome sequencing available. Impact: This study highlights the importance of identification of tumor phenotypes related to colorectal cancer and understanding potential heterogeneity for risk and survival.
Lung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies
Li, Yafang , Xiao, Xiangjun , Li, Jianrong , Han, Younghun , Cheng, Chao , Fernandes, Gail , Slewitzke, Shannon E. , Rosenberg, Susan M. , Zhu, Meng , Byun, Jinyoung , McKay, James , Lam, Stephen , Chen, Chu , Bojesen, Stig E. , Landi, Maria Teresa , Risch, Angela , Wichmann, H-Erich , Goodman, Gary E. , Field, John K. , Shete, Sanjay , Liu, Geoffrey , Andrew, Angeline S. , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E. , Aldrich, Melinda C. , Schwartz, Ann G. , Gorlov, Ivan , Purrington, Kristen S. , Liu, Yanhong , Mandal, Diptasri , Gaba, Colette , Brennan, Paul , Xia, Jun , Fernandes, Gail F , Bossé, Yohan , McKay, James , Albanes, Demetrius , Lam, Stephen , Tardón, Adonina , Chen, Chu , Bojesen, Stig E , Landi, Maria T , Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Wichmann, H-Erich , Christiani, David C. , Rennert, Gad , Arnold, Susanne M , Goodman, Gary E , Field, John K , Davies, Michael P A , Shete, Sanjay , Marchand, Loïc Le , Liu, Geoffrey , Hung, Rayjean J , Andrew, Angeline S , Kiemeney, Lambertus A , Sun, Ryan , Zienolddiny, Shanbeh , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E , Cox, Angela , Hong, Yun‐Chul , Lazarus, Philip J. , Schabath, Matthew B , Aldrich, Melinda C , Schwartz, Ann G , Gorlov, Ivan , Purrington, Kristen S , Yang, Ping , Liu, Yanhong , Wilson, Richard K , Pinney, Susan M , Mandal, Diptasri , Willey, James C , Brennan, Paul , Xia, Jun , Shen, Hongbing , Amos, Christopher I , Han, Younghun , Cheng, Chao , Byun, Jinyoung , Bossé, Yohan , Albanes, Demetrius , Tardón, Adonina , Johansson, Mattias , Bickeböller, Heike , Rennert, Gad , Arnold, Susanne M. , Davies, Michael P.A. , Marchand, Loı̈c Le , Hung, Rayjean J. , Kiemeney, Lambertus A. , Zienolddiny, Shanbeh , Cox, Angela , Schabath, Matthew B. , Yang, Ping , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Willey, James C. , Shen, Hongbing , Amos, Christopher I.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 5, 2024 | Volume: 33 | Issue: 3 | Pages: 389-399

10.1158/1055-9965.epi-23-0613 | PMID 38180474 Get It

Abstract Background: Clinical, molecular, and genetic epidemiology studies displayed remarkable differences between ever- and never-smoking lung cancer. Methods: We conducted a stratified multi-population (European, East Asian, and African descent) association study on 44,823 ever-smokers and 20,074 never-smokers to identify novel variants that were missed in the non-stratified analysis. Functional analysis including expression quantitative trait loci (eQTL) colocalization and DNA damage assays, and annotation studies were conducted to evaluate the functional roles of the variants. We further evaluated the impact of smoking quantity on lung cancer risk for the variants associated with ever-smoking lung cancer. Results: Five novel independent loci, GABRA4, intergenic region 12q24.33, LRRC4C, LINC01088, and LCNL1 were identified with the association at two or three populations (P < 5 × 10−8). Further functional analysis provided multiple lines of evidence suggesting the variants affect lung cancer risk through excessive DNA damage (GABRA4) or cis-regulation of gene expression (LCNL1). The risk of variants from 12 independent regions, including the well-known CHRNA5, associated with ever-smoking lung cancer was evaluated for never-smokers, light-smokers (packyear ≤ 20), and moderate-to-heavy-smokers (packyear > 20). Different risk patterns were observed for the variants among the different groups by smoking behavior. Conclusions: We identified novel variants associated with lung cancer in only ever- or never-smoking groups that were missed by prior main-effect association studies. Impact: Our study highlights the genetic heterogeneity between ever- and never-smoking lung cancer and provides etiologic insights into the complicated genetic architecture of this deadly cancer.
Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
Park, Jung Eun , Nguyen, Vy H. , Tsai, Pei‐Chien , Toyoda, Hidenori , Leong, Jennifer , Guy, Jennifer , Huang, Chung‐Feng , Yasuda, Satoshi , Abe, Hiroshi , Hsu, Yao‐Chun , Tseng, Cheng‐Hao , Liu, Joanne, Chen, Yao‐Li , Lin, Ping‐Yi , Yoshimaru, Yoko , Ishigami, Masatoshi , Enomoto, Masaru , Tamori, Akihiro , Uojima, Haruki , Wang, Xiao Zhong, Xu, Qiang , Takahashi, Hirokazu , Eguchi, Yuichiro , Inoue, Kaori , Zhao, Wen , Barnett, Scott D. , Maeda, Mayumi , Cheung, Ramsey , Landis, Charles , Tanaka, Yasuhito , Roberts, Lewis R. , Schwartz, Myron , Yu, Ming‐Lung , Nguyen, Mindie H. , Yeh, Ming-Lun , Huang, C-F , Tseng, Cheng-Hao , Jun, D W , Ogawa, Eiichi , Huang, Daniel Q , Dai, Chia-Yen , Kumada, Takashi , Yu, M-L , Nguyen, Mindie H , Roberts, Lewis R , Huang, Daniel Q. , Chuang, Wan‐Long , Huang, Jee‐Fu

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 4, 2024 | Volume: 59 | Issue: 6 | Pages: 742-751

10.1111/apt.17863 | PMID 38173278 Get It

SummaryBackgroundRacial and ethnic disparities exist for hepatitis C virus (HCV) treatment and hepatocellular carcinoma (HCC) survival.AimTo evaluate the impact of HCV treatment on such disparities.MethodsIn a retrospective cohort study, we analysed 6069 patients with HCV‐related HCC (54.2% Asian, 30.1% White, 8.5% Black, and 7.3% Hispanic) from centres in the United States and Asia.ResultsThe mean age was 61, 60, 59 and 68, respectively, for White, Black, Hispanic and Asian patients. Black patients were most likely to have Barcelona Clinic Liver Cancer stage D, vascular invasion and distant metastasis (23% vs. 5%–15%, 20% vs. 10%–17% and 10% vs. 5%–7%, respectively; all p < 0.0001). Treatment rate with direct‐acting antiviral agents (DAA) was 35.9% for Asian, 34.9% for White, 30.3% for Hispanic (30.3%), and 18.7% for Black patients (p < 0.0001). Among those untreated or without sustained virologic response (SVR), 10‐year survival rates were 35.4, 27.5, 19.3 and 14.0, respectively, for Asian, Hispanic, White and Black patients (p < 0.0001). There were no statistically significant differences among those with SVR (p = 0.44). On multivariable analysis adjusted for relevant confounders, there was no statistically significant association between survival and being Hispanic (aHR: 0.68, p = 0.26) or Black (aHR: 1.18, p = 0.60) versus White. There was a significant association between being Asian American and survival (aHR: 0.24, p = 0.001; non‐U.S. Asian: aHR: 0.66, p = 0.05), and for SVR (aHR: 0.30, p < 0.0001).ConclusionDAA treatment rates were suboptimal. Racial and ethnic disparities resolved with HCV cure. Early diagnosis and improved access to HCV treatment is needed for all patients with HCV infection.
Comorbid neurotrauma increases neurodegenerative-relevant cognitive, motor, and autonomic dysfunction in patients with rapid eye movement sleep behavior disorder: a substudy of the North American Prodromal Synucleinopathy Consortium
Ligman, Brittany R. , Bryant‐Ekstrand, Mohini , Keil, Allison , Powers, Katherine , Olivo, Cosette, Neilson, Lee E. , Pelletier, Amélie , Gagnon, Jean‐François , Liu, Lang , Forsberg, Leah K. , Fields, Julie A. , Ross, Owen A. , Howell, Michael J. , McLeland, Jennifer , Criswell, Susan R. , Miglis, Mitchell G. , Lee‐Iannotti, Joyce , Ju, Yo‐El S. , Lim, Miranda M. , Locke, Jessica, Amudson-Huffmaster, Sommer, Brushaber, Nellie, Chung, Jae Woo , Kam, Joshua De , Fischbach, Ellen, Ekelmans, Adrian , Keane, Marissa, Kraft, Ruth, MacKinnon, Colum D. , Miner-Rose, Daeva, Murphy, Samantha , Rivera, Adreanne, Sanchez, Sarahmay, Summers, Rebekah L. S. , Tiegan, Luke, Taylor, Leah, Timm, Paul, Tucker, Kelsey, Yu, Erik, Tran, Peter , Galasko, Douglas, Mignot, Emmanuel , Elliott, Jonathan E , Powers, Katherine , Neilson, Lee E , Gan-Or, Ziv , St Louis, E K , Ross, Owen A , Huddleston, Daniel E , Bliwise, Donald L , Avidan, Alon Y , Criswell, Susan R , During, Emmanuel , Miglis, Mitchell G , Boeve, Brad , Lim, Miranda M , Howell, Michael J , Elliott, Jonathan E. , Postuma, Ronald B. , Gan‐Or, Ziv , Yu, Eric , Louis, Erik K. St. , Huddleston, Daniel E. , Bliwise, Donald L. , Avidan, Alon Y. , Schenck, Carlos H. , Videnovic, Aleksandar , Shprecher, David , Boeve, Bradley F. , Duff, Kevin , Choudhury, Parichita , Stauder, Matthew J. , Taylor, Leah

Mayo Clinic

SLEEP | January 4, 2024 | Volume: 47 | Issue: 6 | Pages: No page available

10.1093/sleep/zsae007 | PMID 38181205 Get It

Abstract Study Objectives Rapid eye movement sleep behavior disorder (RBD) is strongly associated with phenoconversion to an overt synucleinopathy, e.g. Parkinson’s disease (PD), Lewy body dementia, and related disorders. Comorbid traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD)—henceforth “neurotrauma” (NT)—increase the odds of RBD by ~2.5-fold and are associated with an increased rate of service-connected PD in Veterans. Thus, RBD and NT are both independently associated with PD; however, it is unclear how NT influences neurological function in patients with RBD. Methods Participants ≥18 years with overnight polysomnogram-confirmed RBD were enrolled between 8/2018 to 4/2021 through the North American Prodromal Synucleinopathy Consortium. Standardized assessments for RBD, TBI, and PTSD history, as well as cognitive, motor, sensory, and autonomic function, were completed. This cross-sectional analysis compared cases (n = 24; RBD + NT) to controls (n = 96; RBD), matched for age (~60 years), sex (15% female), and years of education (~15 years). Results RBD + NT reported earlier RBD symptom onset (37.5 ± 11.9 vs. 52.2 ± 15.1 years of age) and a more severe RBD phenotype. Similarly, RBD + NT reported more severe anxiety and depression, greater frequency of hypertension, and significantly worse cognitive, motor, and autonomic function compared to RBD. No differences in olfaction or color vision were observed. Conclusions This cross-sectional, matched case:control study shows individuals with RBD + NT have significantly worse neurological measures related to common features of an overt synucleinopathy. Confirmatory longitudinal studies are ongoing; however, these results suggest RBD + NT may be associated with more advanced neurological symptoms related to an evolving neurodegenerative process.
Associations between neuropsychiatric symptoms, pathology in neuropathological cohorts of Alzheimer’s disease, Alzheimer’s disease with Lewy bodies and Dementia with Lewy bodies
Shakir, Neha , Belden, Christine M. , Mehta, Shyamal H. , Shill, Holly A. , Driver‐Dunckley, Erika, Beach, Thomas G. , Tremblay, Cécilia , Zhang, Nan , Adler, Charles H. , Driver‐Dunckley, Erika , Serrano, Geidy E. , Atri, Alireza , Choudhury, Parichita

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S18 | Pages: No page available

10.1002/alz.079470 Get It

AbstractBackgroundNeuropsychiatric symptoms (NPS) are frequent in Alzheimer’s Disease dementia (ADD) but a higher NPS burden is found in dementia with Lewy bodies (DLB). Lewy body (LB) pathology frequently co‐occurs with AD pathology and may not meet neuropathological criteria for DLB (ADLB). Previous studies have shown that both ADLB and DLB cases have faster cognitive and/or functional decline compared to AD. However, the differences in NPS severity over disease course and survival in these pathologic subgroups is not well understood.MethodCases from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) with a final neuropathologic diagnosis of DLB (±AD co‐pathology; n = 65), ADLB (n = 89), AD (without LB) (n = 140), and controls (no neuropathological diagnosis) (n = 82) were included. Total NPI‐Q (scores ranging from 0‐36) at time of enrollment and within 2.5 years of death were calculated for all groups. Statistical analysis utilizing ANCOVA (adjusting for age, sex, baseline MMSE and cognitive symptom duration) with pairwise comparisons, and Kaplan‐Meier curves were completed.ResultAge at onset of cognitive symptoms was not different between pathology groups. NPI‐Q scores at enrollment were highest in ADLB (7.33 ± 4.85), and higher (p<0.001) than DLB (5.10 ± 3.37), AD (4.54 ± 3.63) and controls (1.78 ± 1.70). At final evaluation, NPI‐Q scores were highest in DLB (10.04 ± 6.28), followed by ADLB (8.0 ± 4.), and ADD (7.61 ± 5.05) when compared to controls (2.78 ± 3.97) (all p<0.001). DLB and AD demonstrated significant increases in NPI‐Q severity during follow up (p < 0.001). AD had longer survival time (5.8 years) compared to ADLB (4.0 years) and DLB (3.9 years). Subjects with NPS had a shorter median survival time (3.4 years) compared to subjects without NPS (6.5 years; p = 0.002).ConclusionA higher NPS burden and shorter survival is seen in both DLB and ADLB, as compared with AD. This suggests that diffuse neocortical LB pathology is not the major driver of either NPS or survival.
Decline in cognitive trajectories in the neuropathological spectrum of Lewy Body disease
Choi, Alexander S., Belden, Christine M. , Mehta, Shyamal H. , Driver‐Dunckley, Erika, Shill, Holly A. , Beach, Thomas G. , Choudhury, Parichita , Zhang, Nan , Boeve, Bradley F. , Tremblay, Cécilia , Choi, Alexander, Driver‐Dunckley, Erika , Shprecher, David , Serrano, Geidy E. , Atri, Alireza

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S18 | Pages: No page available

10.1002/alz.079086 Get It

AbstractBackgroundPathological Lewy body disease (LBD) may commonly present clinically as Parkinson’s disease dementia (PDD), Dementia with Lewy bodies (DLB) or Alzheimer’s disease dementia (ADD). Neuropathological definitions also include a group in which ADD is present, but the postmortem Lewy pathology does not meet threshold density and distribution levels for the neuropathological diagnosis of DLB (ADLB). Little is known about the cognitive profiles of patients with ADLB and despite common underlying pathology, studies delineating neuropsychological profiles in LBD are fraught with inconsistencies. We characterized the longitudinal cognitive trajectories defined by neuropsychological profiles in cases along the pathological spectrum of LBD.MethodCases from the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) with a cognitive diagnosis of dementia at death and who at minimum, had two neuropsychological evaluations were included. Final neuropathological diagnosis was determined as LBD (neocortical or limbic LB ± AD), ADLB, and AD pathology only. LBD cases were categorized by their cognitive clinical syndromes as PDD and DLB. Global cognition was evaluated using MMSE. Neuropsychological domains of Memory, Executive function, language, attention, and visuospatial were evaluated. Mixed linear methods were used to predict longitudinal change for a given baseline MMSE.Result287 participants and 1874 participant‐years of data were included in this study. LBD (n = 115), and ADLB (52) groups were predominantly male, while AD (n = 114) group was primarily female. Baseline MMSE was similar across all pathologic groups. Linear mixed modelling methods showed faster decrease in memory domain scores (decreasing 0.22 units/year – 0.42 units/year faster, p = 0.01) in ADLB group compared to other groups. Significantly faster decline was noted in LBD and ADLB group in clock drawing (p<0.001), fluency scores (declining 1.02 unit/year faster p<0.001) compared to AD group. There was no difference between PDD and DLB clinical subgroups.ConclusionIn autopsy confirmed cases, ADLB had an accelerated trajectory of decline in memory tasks, while AD, and LBD appeared to have similar trajectories. In contrast, all groups with Lewy bodies progressed faster and showed accelerated decline compared to AD in measures of frontal‐subcortical functions. These results may inform antemortem classification of patients and diagnostic accuracy in these groups.
The Human Brain Nucleus Incertus: A New Target in Dementia?
Intorcia, Anthony J., Suazo, Crystal , Nolz, Jennifer, Tallant, Lauren , Plamondon, Julie, Beach, Thomas G. , Ávila, Camila de , Serrano, Geidy E. , Caron, Alexandre , Gundlach, Andrew L. , Mastroeni, Diego

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.071647 Get It

AbstractBackgroundThe brainstem nucleus incertus (NI) or ‘uncertain nucleus’, was originally described by Streeter in 1903 as a midline region in the floor of the fourth ventricle of the human brain with an ‘unknown’ function. A century later, the NI has been shown to play a key role in memory formation in rodents, through direct and indirect inhibition of the hippocampus; and the anatomy of the NI and its projections throughout the brain have been systematically mapped in rats, mice, and primates, but not in humans. In these novel studies, we mapped the human NI using the neuropeptide, relaxin‐3 (RLN3), as neurochemical marker. In rodents, RLN3 is produced mostly in NI neurons with some subsidiary positive cells in the periaqueductal gray and an area dorsal to the substantia nigra.MethodsSerial, free‐floating coronal sections of formalin‐fixed postmortem tissue were prepared from the pons of an adult female (aged 96 years) without a history of dementia or other neurological disorders, provided by the Banner Brain and Body Donation Program, Sun City, Arizona, USA. Using immunohistochemistry, we first identified the NI by mapping the distribution of microtubule‐associated protein‐2 (MAP2) and RLN3. The specificity of the RLN3 antibody used was verified in a dot‐blot using native RLN3 peptide. We also investigated the presence of markers detected in the NI of rats ‐ glutamic acid dehydrogenase‐65/67 (GAD65/67) and corticotropin‐releasing factor type 1 receptor (CRF1); and used a phosphorylated‐tau (AT8) to determine if the NI displayed tau accumulation.ResultsDetection of MAP2‐immunoreactivity revealed the neuronal distribution throughout the pons. RLN3‐immunoreactivity was detected in neurons in the dorsal, anterior‐medial region, revealing the broad anatomy of the human NI. Neurons within this same area were also positive for GAD65/67‐ and CRF1‐immunoreactivity, in line with previous studies; and AT8‐immunoreactivity was also detected.ConclusionsRLN3 is present in neurons of the human NI and aspects of its anatomy are shared across species, including the macaque. Accumulation of phosphorylated‐tau in the NI suggests its possible involvement in the pathology of Alzheimer’s disease and related dementias. Further comparative studies are required to better understand the neurochemical anatomy of the human NI.
Author Response: Identifying metabolic features of colorectal cancer liability using Mendelian randomization
Tan, Vanessa Y. , Huyghe, Jeroen R. , Li, Li , Pai, Rish K. , Figueiredo, Jane C. , Bull, Caroline J. , Hazelwood, Emma , Bell, Joshua A. , Constantinescu, Andrei‐Emil , Borges, Maria Carolina , Legge, Danny , Burrows, Kimberley , Brenner, Hermann , Castellvı́-Bel, Sergi , Chan, Andrew T. , Kweon, Sun-Seog , Marchand, Loı̈c Le , Cheng, Iona C. , Murphy, Neil , Gunter, Marc J. , Timpson, Nicholas J. , Vincent, Emma E.

Mayo Clinic

No container title available | December 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.87894.3.sa2 Get It

Identifying metabolic features of colorectal cancer liability using Mendelian randomization
Bull, Caroline J. , Hazelwood, Emma , Tan, Vanessa Y. , Legge, Danny , Huyghe, Jeroen R. , Li, Li , Pai, Rish K. , Figueiredo, Jane C. , Bull, Caroline J , Legge, Danny , Hazelwood, Emma , Bell, Joshua A. , Constantinescu, Andrei‐Emil , Borges, Maria Carolina , Burrows, Kimberley , Brenner, Hermann , Castellvı́-Bel, Sergi , Chan, Andrew T. , Kweon, Sun-Seog , Marchand, Loı̈c Le , Cheng, Iona C. , Murphy, Neil , Gunter, Marc J. , Timpson, Nicholas J. , Vincent, Emma E.

Mayo Clinic

eLife | December 21, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.87894.3 Get It

Background: Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. Methods: To investigate whether changes in circulating metabolites characterize the early stages of colorectal cancer (CRC) development, we examined the associations between a genetic risk score (GRS) associated with CRC liability (72 single-nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N = 6221). Linear regression models were applied to examine the associations between genetic liability to CRC and circulating metabolites measured in the same individuals at age 8 y, 16 y, 18 y, and 25 y. Results: The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P < 0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N = 118,466, median age 58 y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk. Conclusions: These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism and suggest that fatty acids may play an important role in CRC development. Funding: This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/ .